hd1-a

Givinostat hydrochloride monohydrate (ITF2357) is an HDAC inhibitor.

11β-HSd1-in-11 is a potent and competitive inhibitor of 11-β-hydroxysteroid dehydrogenase 1 (11β-HSD1) IN rats and humans with IC50 values of 0.34 μM and 0.13 μM, respectively. 11β-Hsvd1-in-11 is a compound used as a chemical compound. 11β-HSD1-IN-11 is a hormone involved in regulating various physiological processes, such as metabolism, inflammation, and stress responses. 11β-Hd1-in-11 is a potential compound for the treatment of metabolic disorders, obesity, and certain inflammatory conditions.

GR 103691, a potent and selective dopamine D3 receptor antagonist (Ki: 0.4 nM), exhibits more than 100-fold selectivity for human dopamine D3 receptors over human D4 and D1 sites.

MC1568 is a specific HDAC inhibitor for maize HD1-A (IC50: 100 nM, in a cell-free assay). It is 34-fold more selective for HD1-A than HD1-B.

Givinostat (ITF-2357) is an HDAC inhibitor with IC50 values of 198 nM for HDAC1 and 157 nM for HDAC3.

Givinostat hydrochloride (ITF2357 hydrochloride) is an inhibitor of HDAC with IC50 of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride exhibits anti-inflammatory, anti-angiogenic, and antineoplastic activities.

PRO-HD1, a PROTAC (proteolysis-targeting chimera) HDAC6 degrader, effectively degrades HDAC6 in A549 cells and inhibits Jurkat cell proliferation with an IC50 of 5.8 µM [1].